Skip to content
Search

Latest Stories

Amitabh Bachchan, Ranbir Kapoor and Alia Bhatt starrer Brahmastra to release in June 2021?

Ayan Mukerji’s Brahmastra has been in the making from the past few years. The movie was supposed to release in 2019, and then the makers postponed it to Summer 2020. A few months ago, they announced that it will hit the screens on 4th December 2020. However, due to the pandemic, the shooting of the film has been stalled, and once again it will get delayed.

According to a report in Mid-day, the makers are planning to resume the shoot in October and are eyeing on June 2021 release. A source told the tabloid, "If the crisis is relatively under control, and things go as planned, the film will go back on floors in October. Ayan has broken down the shoot into two shifts — 9 am to 2 pm, followed by another from 4 pm to 9 pm. There will be two separate minimal crews for the stints, with each unit adhering to on-set safety guidelines. Since producer Karan Johar is eyeing a June 2021 release, Ayan wants to wrap up the shoot latest by December."


The movie stars Amitabh Bachchan, Ranbir Kapoor, Alia Bhatt, Nagarjuna, Mouni Roy and Gurfateh Pirzada. Reportedly, Ayan has to shoot scenes with Big B, Alia, and Mouni.

However, according to the new guidelines actors above the age of 65 years old are not allowed to be on the sets. Also, Big B has tested positive for COVID-19, so we wonder if he will resume work anytime soon. There’s also a theme song shoot left which will be picturized on Ranbir.

Well, let’s hope that soon the shooting of the film gets completed and it hits the big screen. We are sure fans of Ranbir have been eagerly waiting for the movie.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less